| Today's Big NewsMay 8, 2023 |
|
Choosing the best eCOA platform that considers the needs of patients, site staff and data requirements are all critical factors. But it takes more to reach success. Download your eCOA Technology Guide.
|
|
| By Max Bayer The historically slow pace of biotech IPOs in 2022 has kept up so far this year, with just six companies hitting Wall Street so far. |
|
|
|
By Nick Paul Taylor Eisai is joining the HER2 antibody-drug conjugate gold rush. After seeing AstraZeneca and Daiichi Sankyo validate the approach, Eiasi has struck a $2 billion biobucks deal with Bliss Biopharmaceutical for a spot alongside BioNTech in the chasing pack. |
By Nick Paul Taylor Amgen has ended its alliance with Entera Bio. The partners entered into a $270 million, three-molecule deal in 2018 but have agreed to scuttle the collaboration before reaching any major milestones. |
Sponsored by ValGenesis Inc. Cell and gene therapies hold great promise but can also carry serious risks. Applying a risk-based approach during development and manufacturing increases patient safety and product quality. Read more. |
By Max Bayer Exelixis’ board of directors is waving the white flag after a third director targeted by activist investor Farallon Capital Management announced he wouldn’t stand for reelection. |
Sponsored by Precision for Medicine Discover Sofia Baig's vision for clinical research, data-driven insights & patient centricity at Precision for Medicine! |
By Max Bayer Ginkgo Bioworks and Boehringer Ingelheim are linking arms as they venture into the forest of undruggable targets, with the larger pharma offering up to $406 million for Ginkgo’s molecules. |
By Annalee Armstrong If at first you don’t succeed, try again. That’s what NGM Biopharma has done with a previously failed nonalcoholic steatohepatitis candidate, in hopes that it could provide some light at the end of a dark time in the clinic. |
By Zoey Becker After raking in billions with its Pfizer-partnered COVID-19 vaccine, BioNTech is now forced to look for growth elsewhere. |
By Conor Hale The time has come for Tempus to secure its first premarket approval from the FDA, with a green light for a companion diagnostic to help profile the underlying genetic makeup of solid tumors. |
By Fraiser Kansteiner Ahead of a long-awaited advisory committee meeting on Perrigo’s over-the-counter birth control prospect Opill, the FDA says many big questions remain. |
By Andrea Park As Twist Bioscience aims to untangle its operations and focus only on its most potentially profitable work, the synthetic DNA maker is cutting down its workforce. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss how the healthcare industry is addressing its role in climate change. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ Our speaking faculty features leaders from big pharma, small-mid size pharma, biotechs, and more. Save $500 when you. Register Today!
|
|
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
